Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — Berenberg Discover AI Seminar 2022
23 slides from Simulations Plus's conference presentation, Apr 26, 2022
Slide 1: Q2 FY22 Update
1 | NASDAQ: SLP Investor Presentation NASDAQ: SLP Q2 FY22 Update 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement 2 | NASDAQ: SLP With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties . The actual results of the Company could differ significantly from those statements . Fact
Slide 3: About Us
About Us Leading provider of modeling and simulation software and services used by major pharmaceutical, biotech, and regulatory agencies worldwide to make better model - informed data - driven decisions (MIDD). 1996 Founded >150 Employees >10 yrs P r ofi t / r e v gr owth >1300 Publications >70 Sci
Slide 4: Investment Highlights
Investment Highlights 4 | NASDAQ: SLP Leader in software and services for the drug discovery, development, and regulatory approval process Low market penetration + share gain opportunity in large and growing market Double - digit revenue growth with strong operating leverage Accretive M&A Strategy
Slide 5: Our Markets
Our Markets Key Drivers 1. Acceptance & increasing adoption of MIDD technology by industry & regulators 2. Pharma spend rates continue to grow with large allocation towards Biosimulation 3. Biosimulation growing at 4 - 5X total R&D spend SLP growing faster than Biosimulation TAM $176B ³ Annual Pharm
Slide 6: Drug Development Challenges
Drug Development Challenges Avg. cost of $2B and 10+ years to bring a drug to market 1 What candidates? How does the drug move through the body? How is it administered? How is it supposed to work? What is the desired effect? What are the risks? Lead S e l ec ti o n Pharmacology A DMET DMPK T r e a t
Slide 7: Our Value Proposition
Our Value Proposition We create value for our customers by accelerating & reducing the cost of R&D through innovative , science - based software & consulting solutions that optimize treatment options and improve patient lives. Outcomes Patient Efficacy Patient Safety Regulatory Approval 7 | NASDAQ:
Slide 8: How We Help – Software and Services
How We Help – Software and Services Software Most comprehensive & widely recognized tools for MIDD Ongoing development & reinvestment incorporates latest science & ensures seamless UX Services Operational efficiencies that lead to accurate/timely decision making & regulatory reporting Therapeutic, m
Slide 9: Software Solutions Span Drug Development Process
Consulting Services & Regulatory Interactions QSP/QST Other Software Solutions Span Drug Development Process Guiding the path between M&S and pharma R&D Cheminformatics AI ML PBPK/ P B B M Pharmacometrics 9 | NASDAQ: SLP
Slide 10: PBPK/PBBM Solutions
Safety Clinical E ff i cacy AD M ET DMPK T r ea tm en t Regimen Lead Selection Pharmacology Services PBPK/PBBM Preclinical Regulatory Consulting Software PBPK Software Solutions and AI Data Mining 10 | NASDAQ: SLP
Slide 11: QSP/QST Solutions
QSP/QST Solutions Services QSP Consulting QST Consulting Software S afe ty Clinical Effi c a c y A DMET DMPK Treatment Regimen Lead Selection Pharmacology 11 | NASDAQ: SLP
Slide 12: Pharmacometrics Solutions
Pharmacometrics Solutions Services Pharmacometrics Clinical Pharmacology Clinical Regulatory Consulting Software Sa f e ty Clinical Effi c a c y AD M ET DMPK Treatment Regimen Lead Se l e ct i o n Pharmacology 12 | NASDAQ: SLP
Slide 13: Growth Opportunities & Capital Allocation
Product Gaps, Adj a c en c i e s & Extensions Consolidate Fr a g me n ted Market T a ke S h a re Low Pe n e tr a ti o n Rates Growth Opportunities & Capital Allocation » Fill gaps in the current product offerings, expand TAM • R&D - enhance models & develop new tools • M&A - consolidate market, expa
Slide 14: Environmental, Social, and Governance (ESG)
Environmental, Social, and Governance (ESG) Strategic priorities that form the foundation of our sustainability framework and highlights 14 | NASDAQ: SLP
Slide 15: Financials
Financials 6, SimulationsPlus 15 masons Deere
Slide 16: Q2 FY22 Highlights
16 | NASDAQ: SLP Q2 FY22 Highlights +13% R ev enue Growth +40% D ilu t e d EPS Growth +50% Se r v ices B acklog Growth » Demonstrated scientific leadership » New software releases » Key pharma and regulatory collaborations » Results in - line with guidance 48% Adj. E B I T D A Margin* 96% Soft w a r
Slide 17: Q2 FY22 Revenue
Q venue (in millions) +13% T o t a l R e v e nue Growth $5.4 $7.8 $9.8 $5 . 0 $5 . 3 $5.0 $10.4 $14.8 2 Q20 2 Q21 2 Q22 Software Services $13.1 40% 60% Software Services 66% 34% 2Q22 Mix Software Services 2Q21 Mix 17 | NASDAQ: SLP +25% Software R e v e nue G r o w th - 5% Services R e v e nue G r o
Slide 18: Q2 FY22 Revenue Breakdown
Q2 FY22 Revenue Breakdown Software Mix Services Mix 56% PKPD 44% 14% 23% QSP/QST PBPK 19% 30% Other 7% Other 7% 18 | NASDAQ: SLP
Slide 19: Backlog and Services Performance Metrics
$13 $11 $17 2 Q 20 2 Q 21 2 Q 22 Backlog (in millions) Backlog Services Performance Metrics Q2 FY22 Services Performance Metrics Total Projects 53 73 63 27 19 25 37 47 82 - 31 117 139 201 2Q20 PKPD 2 Q 21 QSP/QST PBPK 2 Q 2 2 O t h e r 19 | NASDAQ: SLP
Slide 20: Summary
Sum m ary 20 | NASDAQ: SLP Leader in software and services for the drug discovery, development, and regulatory approval process Low market penetration + share gain opportunity in large and growing market Double - digit revenue growth with strong operating leverage Accretive M&A Strategy
Slide 21: Thank you!
Thank you! Investor Relations Contacts: Brian Siegel Managing Director Hayden IR +1 - 346 - 396 - 8696 brian@haydenir.com Renee Bouche Simu l a ti on s P l us +1 - 661 - 723 - 7723 renee@simulations - plus.com Learn More! www.simulations - plus.com 21 | NASDAQ: SLP
Slide 22: References
References 22 | NASDAQ: SLP 1. Biopharmaceutical Research and Development: The Process Behind New Medicines. www.PhRMA.org, January 2012, Washington, US http://phrma docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf. 2. Brochure: “Biopharmaceutical Research & Development: The Process Beh
Slide 23: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation 23 | NASDAQ: SLP SIMULATIONS PLUS, INC. Reconciliation of Adjusted EBITDA to Net Income (Unaudited) ( i n m i lli o n s) 2021 2022 2021 2022 Q1 Q2 Q3 Q4 Q1 Q2 Fiscal Year Fiscal YTD Net Income Excluding: Interest income and expense, net $ 2.5 (0.1) $ 3.2 (0.0) $ 3.8 (0
Simulations Plus — Berenberg Discover AI Seminar 2022 on 6ix